Stock Traders Purchase Large Volume of Abivax Call Options (NASDAQ:ABVX)

Abivax SA Sponsored ADR (NASDAQ:ABVX) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 6,598 call options on the company. This is an increase of approximately 89% compared to the typical volume of 3,492 call options.

Analysts Set New Price Targets

ABVX has been the topic of several research analyst reports. Citizens Jmp increased their price target on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 16th. Wolfe Research raised Abivax to a “strong-buy” rating in a research report on Thursday, November 6th. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $142.00 price target on shares of Abivax in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $128.73.

Abivax Price Performance

Shares of NASDAQ ABVX traded down $2.12 during mid-day trading on Tuesday, reaching $138.28. The company had a trading volume of 1,355,757 shares, compared to its average volume of 884,306. Abivax has a 1-year low of $4.77 and a 1-year high of $148.83. The stock has a market cap of $10.78 billion, a PE ratio of -33.08 and a beta of 0.49. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $114.53 and a two-hundred day moving average price of $78.02.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million during the quarter. On average, equities analysts anticipate that Abivax will post -2.83 earnings per share for the current year.

Institutional Trading of Abivax

A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE grew its position in Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares during the last quarter. Nantahala Capital Management LLC boosted its position in Abivax by 3.3% during the first quarter. Nantahala Capital Management LLC now owns 1,482,994 shares of the company’s stock valued at $9,269,000 after purchasing an additional 46,947 shares during the last quarter. Paloma Partners Management Co purchased a new position in Abivax in the first quarter valued at about $240,000. Finally, ADAR1 Capital Management LLC grew its stake in Abivax by 46.0% in the first quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company’s stock valued at $13,813,000 after purchasing an additional 696,626 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.